Meta-analysis shows PARP inhibitors as maintenance therapy improve progression free survival in newly diagnosed advanced ...

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a ...

Results from a VHIO-led study show that MYC targeting by Omomyc induces tumor DNA damage in patient-derived preclinical ...

Resistance to initial therapy sets the stage for many other options ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

Inhibiting Fatty Acid Synthase Overcomes PARPi Resistance and Creates an Artificial Synthetic Lethality in Triple-Negative Breast Cancer ...

Novel weapons to counter endocrine therapy resistance and treat progressive disease ...